Germany's Evonik May Curb Spending, Make Acquisitions

Evonik, Germany's second-largest chemical producer behind BASF, posted earnings down nearly 25% for the 2014 first quarter and said it may cut its €6 billion investment budget launched in 2012 by up to 15%.

Klaus Engel, CEO of the Essen-based group said that spending could be delayed and the program might be reduced by 10-15%.

"We are waiting in some major projects here for better market conditions to go ahead with further spending," Engel said in a conference call.

While soft-pedaling capital expenditure, Engel said Evonik would look for acquisitions worth more than €1 billion to strengthen its portfolio. He did not rule out larger takeovers or using equity financing. Minor acquisitions might come in the course of the year, he said.

As a minority partner in the joint venture with Russia's Varshavsky Group, Evonik is building a new plant for amino acid in the Rostow-on-Don region, close to the eastern Ukrainian border. The plant is due to come on stream in in 2014 or 2015.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.